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Abstract
This was a randomized controlled pilot study of Lactobacillus rhamnosus GG versus standard of 
care to prevent gastrointestinal multidrug-resistant organism (MDRO) colonization in ICU 
patients. Seventy subjects were included in analyses. There were no significant differences in 
acquisition or loss of any MDROs (p>0.05). There were no probiotic-associated adverse events.
INTRODUCTION
Infections with multidrug-resistant organisms (MDRO) are a serious threat to critically ill 
patients, leading to increased morbidity and mortality.1,2 Gastrointestinal colonization with 
MDROs increases patients’ risk of infection, and colonized patients are the major reservoir 
for MDRO transmission to other hospitalized patients.3 One potential strategy to prevent 
MDRO colonization is to use probiotics to promote healthy intestinal flora, but data on 
probiotics in ICU patients are limited. We conducted a prospective, randomized controlled 
pilot study to determine if Lactobacillus rhamnosus GG could safely prevent intestinal 
colonization with MDROs in a critically ill population.
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This study was conducted at Barnes-Jewish Hospital (BJH) in St. Louis, MO, a 1,250 bed 
university-affiliated hospital, from February 2012- October 2013, and was approved by the 
Washington University Human Research Protection Office. The primary outcome was the 
acquisition of gastrointestinal MRDO colonization. The secondary endpoints were safety 
and loss of MDRO colonization.
Inpatients age ≥18 admitted to the medical or coronary ICUs with anticipated length of stay 
>48 hours were eligible. Exclusion criteria included: pregnancy, immunosuppression, HIV 
with CD4 <200 cells/mcl, absolute neutrophil count <500 K/cumm, transplant recipients, 
ongoing chemotherapy, prosthetic valve or valvuloplasty, vascular graft, left ventricular 
assist device (LVAD), balloon pump, cardiac arrest, cardiac trauma, pancreatitis, 
endocarditis, history of rheumatic fever, congenital cardiac abnormality, tracheostomy, 
gastrointestinal bleeding or injury, esophageal varices, oropharyngeal mucosal injury, 
diarrhea, and unwillingness or inability to consent.
Subjects were randomly assigned to the probiotic or standard of care group (SOC) in a 1:1 
ratio using permutation blocks (n=4 per block) by APACHE II scores. Study assignment 
was unblinded. Subjects randomized to the probiotic group received 1 capsule containing 
1010 cells of L. rhamnosus GG (Culturelle, i-Health, Inc., Cromwell, CT) twice a day. If 
subjects were unable to swallow due to intubation or presence of a nasogastric tube, the 
probiotic was administered in a saline slurry via syringe through the tube after removal of 
the gelatin capsule. Subjects in the probiotic group received probiotic for 14 days or until 
study exit (death or hospital discharge), whichever came first.
Stool samples or rectal swabs were obtained at study enrollment (prior to the first dose of 
probiotic), study day 3, and every 3 days until study exit. Study exit was defined as death or 
day 14 post-enrollment, whichever came first. Patients were included in outcomes analyses 
if they had ≥3 samples. Acquisition of MDRO was defined as negative cultures on 
enrollment and positive cultures on day 3 and/or at study exit. Loss of MDRO colonization 
was defined as positive cultures on enrollment and negative cultures on day 3 and study exit.
Selective media were used to isolate MDROs as follows: HardyCHROM™ CRE Agar 
(Hardy Diagnostics, Santa Maria, CA) for CRE, ChromID® VRE agar (bioMerieux, 
Durham, NC) for VRE, HardyCHROM™ ESBL Agar (Hardy Diagnostics, Santa Maria, CA) 
for ESBL and HardyCHROM™ ChromID® Pseudomonas (Biomerieux, Durham, NC) agar 
for Pseudomonas. Cycloserine-cefoxitin mannitol broth with taurocholate lysozyme cysteine 
(Anaerobe Systems, Morgan Hill, CA) was used for C. difficile culture as previously 
published.4 Organisms recovered from selective media were identified using VITEK MS 
matrix-assisted laser desorption ionization-time of flight mass spectrometry system, IVD 
v2.0 (bioMerieux).
Data collected included demographics, medical history, APACHE II scores, length of stay, 
type of intensive care unit, inpatient medication exposures, ventilation status, hospital 
mortality, and diagnosis of infections due to L. rhamnosus GG. Chi-square tests, univariate 
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logistic regression, and Mann-Whitney U tests were performed as appropriate. A p ≤ 0.05 
was considered significant. SPSS version 21 (IBM, Armonk, NY) was used.
RESULTS
One hundred three patients were enrolled and randomized to probiotics or standard of care 
(SOC). 70 patients had at ≥3 specimens available for analyses: 30 (43%) in the probiotic 
group and 40 (57%) in the SOC group. There were no significant differences between 
groups in demographics, pre-enrollment length of stay, or severity of illness (Table 1). There 
was a trend towards older age in the probiotic group (median age=65 years vs. 59, p=0.06). 
Patients in the probiotic group were more likely to have received aztreonam prior to 
enrollment (17% vs. 0; p=0.01); (Table 1).
Colonization status throughout enrollment is summarized in Table 2. There was no 
significant difference in colonization with any MDROs on enrollment (43% of probiotic 
group vs. 33% of SOC group; p=0.35). Only one subject was colonized with an ESBL and 
one with P. aeruginosa at enrollment. More patients were colonized with VRE and C. 
difficile, and rates were similar between groups (p=0.34 and p=0.80, respectively).
There was no significant difference in overall acquisition of any MDROs between the two 
groups (10% of probiotic group vs. 15% of SOC group; p=0.72). Two (7%) patients in the 
probiotic group acquired ESBL colonization (p=0.19). 17% of the probiotic group vs. 9% in 
the SOC group acquired VRE (p=0.42). 7% patients in the probiotic group and 8% SOC 
acquired P. aeruginosa (p=>0.99). No patients in the probiotic group and 7% in the SOC 
group acquired C. difficile (p=0.50).
The single patient colonized with an ESBL-producing Enterobacteriaceae on enrollment 
(SOC group) remained colonized throughout hospitalization. No patients in any group lost 
colonization with VRE or P. aeruginosa. One SOC patient lost C. difficile colonization (p>.
99).
All 103 patients were included in the safety assessment. There were no significant 
differences between probiotic and standard of care patients in the number of patients who 
died (22% probiotic group vs. 21% SOC; p=0.88). There were no infections due to probiotic 
or clinical cultures positive for L. rhamnosus GG in either group. No adverse events 
associated with the probiotic occurred.
DISCUSSION
No differences in acquisition or loss of MDRO colonization between the probiotic and SOC 
group were identified in this study. These results may indicate that either our sample size 
was not large enough to detect a difference between groups, our study duration was too 
short, or that L. rhamnosus GG at the dose used did not affect MDRO colonization. There 
were no infections related to probiotics, suggesting that probiotics may be safe in a select 
cohort of critically ill patients, with care to minimize probiotic contamination when 
administered by tube.
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Previous studies evaluating probiotics have had conflicting results.5–8 A meta-analysis 
found that probiotics in critically ill adults did not significantly reduce mortality but did 
reduce ICU-acquired pneumonia and ICU length of stay.9 Another meta-analysis indicated 
probiotics were associated with reductions in infectious complications but had no effect on 
mortality or length of stay.10 These differences may be due to varying sample size, rates of 
MDRO carriage, types and doses of probiotic used, or the underlying complexity of the 
microbiome.
This study has limitations, including small sample size, duration of follow-up, and inclusion 
of a single type and dose of probiotic. We did not survey for gastric or upper airway 
colonization, which may be an important site for MDRO colonization. Finally, our extensive 
exclusion criteria may limit the generalizability of this study.
There are unresolved controversies regarding probiotics, including the type of patients who 
may benefit most from probiotics, the ideal probiotic organism(s) and dose. The effect of 
prolonged probiotic administration on the gut microbiome is an area for further 
investigation. Future, larger, studies are needed to evaluate the effectiveness of probiotics in 
preventing intestinal colonization due to MDROs in critically ill patients.
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Flowchart of study protocol. #Submitted < 3 samples. *Submitted ≥ 3 samples.
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TABLE 2
Colonization Status Throughout Enrollment
Organism Probiotic (n = 30) Standard of Care (n =40) P value
Colonization at enrollment
 ESBL/CRE 0 (0) 1 (3)a >.99
 VRE 7 (23) 5 (13) .34
 Pseudomonas aeruginosa 1 (3) 0 (0) .43
 Clostridium difficile 6 (20) 9 (23) .80
Acquisition of colonizationb
 ESBL/CRE 2/30 (7) 0/39 (0) .19
 VRE 4/23 (17) 3/35 (9) .42
 P. aeruginosa 2/29 (7) 3/40 (8) >.99
 C. difficile 0/24 (0) 2/31 (6) .50
Loss of colonizationc
 ESBL/CRE N/A 0/1 (0)
 VRE 0/7 (0) 0/5 (0)
 P. aeruginosa 0/1 (0) N/A
 C. difficile 0/6 (0) 1/9 (11) >.99





Negative culture results on enrollment and positive culture results on day 3 and/or study exit, excluding those colonized at day 0.
c
Positive culture results on enrollment and negative culture results on day 3 and/or study exit.
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